A major chemical manufacturer, which was conducting clinical trials aimed at treating myocardial infarction using special cells called "Muse cells" that are said to change into cells of various tissues in the body, announced that it has stopped developing a treatment. Did.
Groups such as Tohoku University, which discovered these cells, are aiming for practical application by calling on other companies to participate in clinical trials.
"Muse cells" are special cells that are said to have the ability to change into cells of various tissues of the body discovered by Professor Mari Dezawa of Tohoku University. It is said that there is work to do.
Regarding the treatment method of administering "Muse cells" to patients with myocardial infarction and cerebral infarction, an affiliated company of the major chemical manufacturer "Mitsubishi Chemical Group" has been conducting clinical trials since 2018, but the company plans to commercialize it on the 14th. It has announced that it will stop development and give up applying for approval as a treatment.
On the other hand, although we will not apply for approval, we will carry out the clinical trials currently underway to the end and publish the results of analyzing the data.
At a press conference held in Tokyo on the 14th, Professor Idezawa said, "I'm very confused when I was suddenly informed of the cancellation of development. I want to find a partner who can properly respond," and called on other companies to participate in clinical trials. He then showed the idea of aiming for practical application.